Navigation Links
Malaria: New Treatment is Upcoming
Date:1/16/2009

ROME, January 16 /PRNewswire/ -- The results of two new large scale trials show that the combination of dihydroartemisinin and piperaquine (DHA+PQP) not only is effective against uncomplicated malaria in a way which is comparable to other artemisinin-based combination therapies (ACTs), but it also protects patients against new infections for at least two months after treatment. The DHA/PQP combination is very well tolerated with no significant side effects.

These notable results were presented at the 57th Annual Meeting of the American Society of Tropical Medicine & Hygiene (ASTMH) held in New Orleans, Louisiana, USA, (December 7-11, 2008). The results demonstrate the benefits of a treatment which is effective against a neglected disease contracted by 400-500 million people worldwide every year and the cause of death of over 1 million people, sadly largely children under 5 in Sub-Saharan Africa.

"If not promptly and effectively treated, malaria can kill in just a few days after the onset of symptoms," said Prof. Umberto D'Alessandro, Prince Leopold Institute of Tropical Medicine, Antwerp, Belgium, coordinator of one of the trials. "This novel medication expands the treatment arsenal available to us, delivers immediate benefits because it acts rapidly, and unquestionably provides help to the populations of Africa and Asia, who are the hardest hit by the disease, but also to Westerners who visit those countries for business or pleasure."

Developed by sigma-tau, the new ACT meets WHO clinical evidence-based treatment strategy recommendation as it is a medication combining in a single tablet the highly potent artemisinin-based active ingredient which does not stay long in the body with a second antimalarial which stays longer in the body. This combination treatment is to be taken only for three days and facilitates the mutual protection of the two active ingredients against drug resistance.
'/>"/>

SOURCE sigma-tau
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. BioTrends Releases TreatmentTrends(TM): US Nephrology, an Ongoing Syndicated Publication Providing Insight into Physician Perceptions and Management of Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism
2. Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients
3. Aegera Therapeutics Initiates A Randomized Phase 2 Combination Study of AEG35156 for 1st Line Treatment of Non-Small Cell Lung Cancer
4. Video: Allergan Announces U.S. Food and Drug Administration (FDA) Approval of Latisse(TM) -- First and Only Treatment Approved by the FDA for Hypotrichosis of Eyelashes
5. Phase 3 Data Demonstrate Efficacy and Tolerability of Paliperidone Palmitate, an Investigational Long-Acting Therapy for the Treatment of Schizophrenia
6. Beyond Seizure Control in the Treatment of Epilepsy With New Anti-Epileptic Drug, Zebinix(TM)
7. Data Presented at ASH Annual Meeting Indicates the Potential of T-Cell Engaging BiTE Antibody Blinatumomab as a Consolidation Treatment for Aggressive Leukemias
8. Advanced Life Sciences Announces Cethromycin NDA Accepted for Filing by FDA for the Treatment of Community Acquired Pneumonia
9. Vasomotor Symptoms? Create an Individual Treatment Plan for Your Patient
10. New Publications Show Noninvasive Magnetic Resonance-Guided Focused Ultrasound to be a Potentially Safe, Effective Pain-Relieving Treatment for Bone Metastases
11. ZhenSpa.com provides Spa Enthusiasts Affordable Alternatives for Expensive Spa Treatments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 23, 2014 Sigma-Aldrich Corporation ... the waiting period under the Hart-Scott-Rodino Antitrust Improvements ... expired on December 22, 2014, thereby completing the ... for the acquisition of the Company by Merck ... clearance satisfies another condition to closing the transaction, ...
(Date:12/22/2014)... VANCOUVER , Dec. 22, 2014 /PRNewswire/ - RepliCel ... stage regenerative medicine company focused on the development of ... paper out of the University of Calgary in conjunction ... North Carolina, which further validates the company,s ongoing clinical ... the effects of pattern baldness. The paper ...
(Date:12/22/2014)... December 22, 2014 ITRA Global, one ... occupiers of commercial real estate, has further expanded its ... in Perth and Brisbane, Western Australia, reports Mylinda Vick, ... , ITRA Global / ACORPP (Australian Corporate Property ... consultancy company providing property services to a wide range ...
(Date:12/19/2014)... 19, 2014 Naurex Inc., a biopharmaceutical company ... diseases of the central nervous system, today announced that ... officer, will present at the 33 rd annual ... place at 3:00 p.m. PST on Tuesday, January 13, ... San Francisco, Calif. About ...
Breaking Biology Technology:Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5ITRA Global Continues International Expansion in Perth and Brisbane, Australia 2Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2
... 7 Cyberonics, Inc. (Nasdaq: CYBX ) today ... Food and Drug Administration ("FDA") to amend the protocol of ... VNS TherapyTM.Based on a reassessment of the study power and ... data analysis originally specified in the study protocol, the company ...
... Calif., Jan. 7 Codexis, Inc. today announced,a licensing ... publicly-undisclosed generic product, using a proprietary Codexis,biocatalyst. Teva, ... a,leading producer of this generic product. The product ... the United States. , Under ...
... Corporation, a leading,developer of targeted, systemic RNA interference ... the final tranche of its Series B,financing. Astellas ... investor, Lilly Ventures, also participating. The addition ... to $21.4 million. Intradigm will,use Series B ...
Cached Biology Technology:Cyberonics Provides Business Update on Depression Clinical Trial 2Cyberonics Provides Business Update on Depression Clinical Trial 3Codexis, Teva in Licensing Agreement Final 2Intradigm Closes Final Tranche of $21.4 Million Series B Financing 2Intradigm Closes Final Tranche of $21.4 Million Series B Financing 3
(Date:12/11/2014)... 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition of ... report to their offering. One ... adoption of multimodal biometric systems. Multimodal biometric systems ... for verification and identification purposes. This helps to ...
(Date:12/10/2014)... 8, 2014 You,ve been here before: you desperately ... remember your password, site key or the answer to your ... grade teacher? Today, Hoyos Labs , ... that will finally put an end to the frustration that ... . 1U leverages a user,s smartphone to acquire his ...
(Date:12/10/2014)... -- CIE San Diego has launched an innovative trust ... that enhances care coordination among social service and care ... earned a second $1 million grant from the Alliance ... in community and; will be recognized as a "Live ... 4-6p. CIE San Diego today announced the ...
Breaking Biology News(10 mins):Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4
... for Agricultural Research and Development, and the company FARMARABA ... produce Omega 3 using marine plant micro-organisms. The ultimate ... highly valued fatty acid, and then apply them at ... centre, which has proven experience in the biotechnology and ...
... Children living near toxic waste sites in ... Indonesia may experience higher blood lead levels, resulting in a ... retardation, according to a study presented today by Kevin Chatham-Stephens, ... Medicine at Mount Sinai, at the Pediatric Academic Societies (PAS) ...
... than two million people in the United States suffer ... abnormal nerve cell firing in the brain which often ... therapies reduce seizures in about two-thirds of patients, the ... therapy and those who take drugs can experience harmful ...
Cached Biology News:Neiker-Tecnalia and FARMARABA produce Omega 3 using marine plant micro-organisms 2Children living near toxic waste sites experience higher blood lead levels resulting in lower IQ 2
...
Borosilicate Glass. Certified for use with the Beacon 2000 Systems, 1,000 tubes/case...
Standard 2" and 3" Fiberboard Boxes can be sold separately or with 16, 25, 36, 49, 64, 81 or 100 cell dividers. Fiberboard boxes can also be ordered with corresponding freezer racks...
Borosilicate Glass. Certified for use with the Beacon 2000 Systems, 1,000 tubes/case...
Biology Products: